loading
前日終値:
$190.02
開ける:
$189.71
24時間の取引高:
401.10K
Relative Volume:
0.53
時価総額:
$3.83B
収益:
$1.77M
当期純損益:
$-123.74M
株価収益率:
-19.81
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+215.78%
1か月 パフォーマンス:
+274.72%
6か月 パフォーマンス:
+403.34%
1年 パフォーマンス:
+150.66%
1日の値動き範囲:
Value
$178.02
$192.96
1週間の範囲:
Value
$156.41
$205.89
52週間の値動き範囲:
Value
$26.70
$205.89

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name
名前
Praxis Precision Medicines Inc
Name
セクター
Healthcare (1145)
Name
電話
617-300-8460
Name
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
Name
職員
82
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
PRAX's Discussions on Twitter

PRAX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PRAX
Praxis Precision Medicines Inc
181.86 4.00B 1.77M -123.74M -95.21M -9.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.54 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.14 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
582.73 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
815.41 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.12 34.68B 4.56B -176.77M 225.30M -1.7177

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-02 再開されました Oppenheimer Outperform
2025-05-07 開始されました Chardan Capital Markets Buy
2025-03-03 繰り返されました H.C. Wainwright Buy
2025-02-11 開始されました Deutsche Bank Buy
2024-08-05 開始されました Oppenheimer Outperform
2024-06-24 開始されました Needham Buy
2024-06-18 開始されました Guggenheim Buy
2024-05-01 開始されました Robert W. Baird Outperform
2023-09-19 開始されました Truist Buy
2022-06-06 ダウングレード Wedbush Outperform → Neutral
2021-12-16 開始されました H.C. Wainwright Buy
2021-08-26 開始されました BofA Securities Buy
2021-04-26 開始されました William Blair Outperform
2020-11-11 開始されました Wedbush Outperform
2020-11-10 開始されました Cowen Outperform
2020-11-10 開始されました Evercore ISI Outperform
2020-11-10 開始されました Piper Sandler Overweight
すべてを表示

Praxis Precision Medicines Inc (PRAX) 最新ニュース

pulisher
08:11 AM

Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor - Insider Monkey

08:11 AM
pulisher
Oct 21, 2025

Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

What institutional flow reveals about Praxis Precision Medicines Inc.Market Movement Recap & Community Driven Trade Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade

Oct 21, 2025
pulisher
Oct 21, 2025

Multi asset correlation models including Praxis Precision Medicines Inc. - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView

Oct 21, 2025
pulisher
Oct 21, 2025

12 Reddit Stocks That Will Go to the Moon - Insider Monkey

Oct 21, 2025
pulisher
Oct 21, 2025

Applying big data sentiment scoring on Praxis Precision Medicines Inc.Stop Loss & Verified Stock Trade Ideas - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 08:35:46 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView

Oct 20, 2025
pulisher
Oct 20, 2025

Largest borrow rate increases among liquid names - TipRanks

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 07:35:45 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener

Oct 20, 2025
pulisher
Oct 20, 2025

Praxis Precision Medicines Announces Underwritten Offering - TradingView

Oct 20, 2025
pulisher
Oct 19, 2025

Praxis surges after late-stage trial success for movement disorder therapy - MSN

Oct 19, 2025
pulisher
Oct 19, 2025

Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN

Oct 19, 2025
pulisher
Oct 18, 2025

Is Praxis Precision Medicines Inc. stock undervalued vs historical averagesPortfolio Return Summary & Safe Capital Growth Trade Ideas - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Praxis Precision Medicines (PRAX) Is Up 256.7% After Positive Phase 3 Results for Essential Tremor Drug - simplywall.st

Oct 18, 2025
pulisher
Oct 18, 2025

Is Praxis Precision Medicines Inc. stock a buy on dipsJuly 2025 Fed Impact & Verified Stock Trade Ideas - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 17, 2025

Major Investment Alert: Adage Capital’s Bold Move in Praxis Precision Medicines! - TipRanks

Oct 17, 2025
pulisher
Oct 17, 2025

Is Praxis Precision Medicines Inc. stock cheap at current valuationJuly 2025 Sector Moves & Long-Term Safe Investment Ideas - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

PRAX underwritten deal: $157/share, warrants; $567M net proceeds - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

PRAX prices common stock and pre-funded warrants; proceeds ~$493.0M - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines, Inc.Common Stock (NQ: PRAX - FinancialContent

Oct 17, 2025
pulisher
Oct 17, 2025

Can Praxis Precision Medicines Keep Climbing? - timothysykes.com

Oct 17, 2025
pulisher
Oct 17, 2025

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Shares Skyrocket: Too Late to Buy? - StocksToTrade

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines: A New High? - timothysykes.com

Oct 17, 2025
pulisher
Oct 17, 2025

Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday - Benzinga

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision (PRAX) Triples on Stellar Drug Trial Results - Insider Monkey

Oct 17, 2025
pulisher
Oct 17, 2025

Ulixacaltamide Trial Success Propels PRAX - StocksToTrade

Oct 17, 2025
pulisher
Oct 17, 2025

Boston biotech raises $525M after stock triples on late-stage drug trial results - The Business Journals

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? - Yahoo Finance

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines (PRAX) Stock Soars After Essential Tremor Drug Success - parameter.io

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines, Inc. (PRAX) Stock: Soars 183% Following $525M Public Offering Announcement - parameter.io

Oct 17, 2025
pulisher
Oct 17, 2025

HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

Oct 17, 2025
pulisher
Oct 17, 2025

Deutsche Bank Boosts Price Target on Praxis Precision Medicines to $280 From $65, Keeps Buy Rating - MarketScreener

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines extends rally after $525 mln stock sale - TradingView

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis: Back From The Dead, Ulixacaltamide Returns In Essential Tremor With Caveats (PRAX) - Seeking Alpha

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines Reaches Analyst Target Price - Nasdaq

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines prices $525 million public offering By Investing.com - Investing.com Nigeria

Oct 17, 2025
pulisher
Oct 17, 2025

Why Praxis Precision Medicines Stock Skyrocketed - TipRanks

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win - Stocktwits

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines Prices $525 Million Share Offering - MarketScreener

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines prices $525 million public offering - Investing.com India

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines (PRAX) Aims to Raise $525M Through Pu - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines prices $525M public offering - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

A Look at Praxis Precision Medicines (PRAX) Valuation Following Positive Phase 3 Results in Essential Tremor - simplywall.st

Oct 17, 2025
pulisher
Oct 17, 2025

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering - Investing News Network

Oct 17, 2025
pulisher
Oct 16, 2025

Praxis Precision Medicines Announces Pricing of $525 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Oct 16, 2025

Praxis Precision Medicines Inc (PRAX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Praxis Precision Medicines Inc (PRAX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Nemiroff Alex
General Counsel and Secretary
Nov 14 '24
Option Exercise
56.94
7,583
431,776
18,540
Nemiroff Alex
General Counsel and Secretary
Nov 14 '24
Sale
80.20
8,239
660,827
10,301
Mastrocola Lauren
Principal Accounting Officer
Nov 14 '24
Option Exercise
56.94
4,374
249,056
10,801
Mastrocola Lauren
Principal Accounting Officer
Nov 14 '24
Sale
81.78
5,188
424,318
5,613
$37.27
price down icon 0.55%
$87.82
price up icon 0.60%
$30.04
price down icon 0.30%
$105.68
price down icon 1.07%
$159.97
price down icon 3.23%
biotechnology ONC
$313.12
price down icon 0.72%
大文字化:     |  ボリューム (24 時間):